

# Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- [Perspective Therapeutics, Inc.](#) ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that its senior management will participate in panel discussions and company presentations at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit in New York, NY on October 8, 2024 and the JonesResearch Virtual Radiopharma Day on October 29, 2024.

## Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit

### **The Next Wave of TRTs - Targets, Targeting Technologies and Isotopes**

Format: Panel

Time: 9:30 a.m. - 10:30 a.m. ET

### **Supply Chain Challenges and Controversies: Ac225 Availability, Pb212 Logistics, The Last Mile**

Format: Panel

Time: 10:50 a.m. - 11:35 a.m. ET

### **Company Presentations**

Format: Presentation

Time: 1:30 p.m. ET

## JonesResearch Virtual Radiopharma Day

Format: Panel

Webcast events can be accessed live, and replays will be archived for 90 days and available through the [Investors page](#) on the Perspective website.

## **About Perspective Therapeutics, Inc.**

Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope  $^{212}\text{Pb}$  to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT- $\alpha$ -NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary  $^{212}\text{Pb}$  generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company's website at [www.perspectivetherapeutics.com](http://www.perspectivetherapeutics.com).

## **Safe Harbor Statement**

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things,

the Company's ability to pioneer advanced treatment applications for cancers throughout the body; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting peptides provide the opportunity to personalize treatment and optimize patient outcomes; the Company's expectation that its "theranostic" approach enables the ability to see specific tumors and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to develop a proprietary <sup>212</sup>Pb generator to secure key isotopes for clinical trial and commercial operations; the Company's clinical development plans and the expected timing thereof; the expected timing for availability and release of data; expectations regarding the potential market opportunities for the Company's product candidates; the potential functionality, capabilities, and benefits of the Company's product candidates and the potential application of these product candidates for other disease indications; the Company's expectations, beliefs, intentions, and strategies regarding the future; the Company's intentions to improve important aspects of care in cancer treatment; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at [www.sec.gov](http://www.sec.gov). Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:

Annie Cheng

[ir@perspectivetherapeutics.com](mailto:ir@perspectivetherapeutics.com)

Russo Partners, LLC

Nic Johnson

[PerspectiveIR@russopr.com](mailto:PerspectiveIR@russopr.com)



10/7/2024 7:00:00 AM